Text this: WCN25-3889 CLINICAL PROFILE OF RENAL ALLOGRAFT RECIPIENTS SWITCHED TO MTOR INHIBITOR-BASED REGIMEN FROM TACROLIMUS AND MYCOPHENOLATE BASED REGIMENS: A SINGLE-CENTER RETROSPECTIVE OBSERVATIONAL STUDY